Bristol-Myers Squibb (BMY), schizophrenia, anti-cancer drugs, AI "achieving results simultaneously"… demonstrating pipeline competitiveness

Bristol-Myers Squibb (BMY) has achieved clinical results and regulatory progress in core therapeutic areas such as mental health, cardiovascular disease, and oncology, further validating the competitiveness of its R&D pipeline. BMY has demonstrated a strengthened momentum for medium to long-term growth through a series of wide-ranging achievements, from the clinical transition of a new drug for schizophrenia to the expansion of indications for immuno-oncology drugs, and collaborations in AI-based diagnostics.

Firstly, the clinical transition of the schizophrenia treatment drug “Caplyta” has yielded positive results. Among patients switched from existing oral atypical antipsychotics to Caplyta, about 86% completed the 8-week treatment, with no cases of treatment interruption due to insufficient efficacy. PANSS scores improved by -4.2 points in the 4-week taper group and by -3.1 points in the 2-week taper group. Although 49% of patients reported treatment-related adverse events, no serious side effects occurred. The industry has noted that it maintained safety characteristics consistent with previous EMERGENT studies.

In the cardiovascular field, AI-based diagnostic technology partnerships have also garnered significant attention. The “Viz HCM,” co-developed with Viz.ai, is the first FDA-approved AI algorithm for detecting hypertrophic cardiomyopathy through standard 12-lead electrocardiograms and has diagnosed 11 new patients in real clinical settings. Furthermore, among patients who tested positive for AI detection but had no phenotype, 13% progressed to disease within approximately 2.7 years. This indicates that BMY’s business is expanding into the digital health sector.

Collaborations in the field of neurodegenerative diseases have also been expanded. In the joint research on amyotrophic lateral sclerosis with Inscitro, two new targets were added, and research results related to TDP-43 abnormalities, which are associated with about 97% of ALS patients, were achieved. Notably, in the iPSC-based motor neuron model, recovery of nerve growth and reduction of genetic abnormalities were confirmed, enhancing the potential for treatment.

The cardiomyopathy treatment drug “Camzyos” has shown positive results in a Phase 3 trial targeting adolescents, and efficacy and safety have been maintained in real clinical data for up to 5 years. It has been approved in over 60 countries, with more than 22,000 patients using it in the United States. However, due to the risk of reduced left ventricular ejection fraction, it can only be supplied under the REMS program.

The immuno-oncology drug “Nivolumab” has also added results for expanded indications. It has been approved in the United States for first-line treatment of classical Hodgkin lymphoma in patients aged 12 and older for stages 3 and 4, and in Europe, its usage has been expanded to the relapsed/refractory patient population. Phase 3 SWOG 1826 study showed that it reduced the risk of disease progression or death by 58%, but the incidence of serious adverse events reached 39%, which has been assessed as a burden factor.

The multiple myeloma candidate therapy “Idecabtagene vicleucel” combined therapy has also significantly improved progression-free survival, demonstrating its clinical value. If overall survival data is obtained in the future, its commercial potential is expected to further increase.

In the field of autoimmune diseases, “Abrocitinib” has received FDA approval for the indication of psoriatic arthritis. In key clinical trials, its ACR20 response rate reached as high as 54%, showing a significant improvement compared to placebo, but safety issues unique to JAK inhibitors, such as the risk of infections and malignancies, still require ongoing management.

On the other hand, BMY has maintained a quarterly dividend of $0.63 per share, continuing its shareholder return policy. As the release of the first-quarter results for 2026 is scheduled for April 30, the market is closely watching how the recently achieved clinical and approval results will reflect in the performance.

Commentary from the industry suggests that BMY is transitioning from a traditional pharmaceutical company to one focused on AI and precision medicine. However, safety risks associated with some pipelines and intensified competition have been pointed out as potential factors for future stock price volatility.